Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
MLTX

MoonLake Immunotherapeutics (MLTX) stock: insider trades, news & valuation

Net selling
Close · Oct 9, 2026 $10.82 +2.3% on the day +15.4% over 12 months 52-week range $9.12 – $22.16

Share price and insider trades

MLTX closeInsider buyInsider sale
510152025NovDecJan 2026FebMarAprMayJunJulAugSepOctSold $22,000 on 2026-07-27 · Kristian ReichSold $47,453 on 2026-04-14 · Matthias BodenstedtSold $48,960 on 2026-07-22 · Kristian ReichSold $54,762 on 2026-06-18 · Matthias BodenstedtSold $273,333 on 2026-05-11 · Matthias BodenstedtSold $322,261 on 2026-07-15 · Kristian ReichSold $679,059 on 2026-07-09 · Da Silva Jorge SantosSold $862,205 on 2026-06-22 · Matthias BodenstedtSold $877,933 on 2026-07-20 · Kristian ReichSold $935,000 on 2026-06-16 · Kristian ReichSold $944,500 on 2026-06-15 · Kristian ReichSold $945,645 on 2026-04-13 · Da Silva Jorge SantosSold $956,933 on 2026-07-01 · Da Silva Jorge SantosSold $1,001,000 on 2026-07-21 · Kristian ReichSold $1,268,314 on 2026-06-17 · Kristian Reich, Matthias BodenstedtSold $1,367,146 on 2026-07-10 · Da Silva Jorge SantosSold $1,626,378 on 2026-04-09 · Matthias BodenstedtSold $1,844,075 on 2026-04-10 · Da Silva Jorge Santos, Matthias BodenstedtSold $2,066,362 on 2025-12-09 · Da Silva Jorge Santos, Kristian ReichSold $3,920,800 on 2025-12-08 · Da Silva Jorge Santos, Kristian ReichSold $62,962,500 on 2026-03-31 · Mark N Lampert
Bought, 12 months$99K
Sold, 12 months$83.0M
Insiders buying1
Insiders selling4

MoonLake Immunotherapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $99K and 4 sold $83.0M of MLTX stock on the open market.

MLTX insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q3 2025: $46.9M sold (5 trades)Q3 2025Q4 2025: $99K bought (1 trades)$99KQ4 2025: $6.0M sold (4 trades)Q4 2025Q1 2026: $63.0M sold (3 trades)Q1 2026Q2 2026: $8.8M sold (12 trades)Q2 2026Q3 2026: $5.3M sold (8 trades)Q3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026—0$5.3M8
Q2 2026—0$8.8M12
Q1 2026—0$63.0M3
Q4 2025$99K1$6.0M4
Q3 2025—0$46.9M5

Valuation, profit and volume

P/E (trailing)n/aSector median —
Market value— 
Profit margin—Revenue growth —
Volume vs. 50-day1.7×Last 5 sessions
Insiders' paper profit+$19KOn all tracked purchases +19.0%

Summary

Over the past 12 months, 1 MoonLake Immunotherapeutics insider reported open-market purchases totaling $99K, while 4 insiders reported sales totaling $83.0M. 18 of 32 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Jul 29SEC Kristian ReichChief Scientific Officer Sell Plan 1,1002,711,198 held (−0%) $20.00 $22K -45.9% —
Jul 23SEC Kristian ReichChief Scientific Officer Sell Plan 50,0002,714,746 held (−2%) $20.02 $1.0M -46.0% —
Jul 23SEC Kristian ReichChief Scientific Officer Sell Plan 2,4482,712,298 held (−0%) $20.00 $49K -45.9% —
Jul 21SEC Kristian ReichChief Scientific Officer Sell Plan 43,7002,764,746 held (−2%) $20.09 $878K -46.1% —
Jul 20SEC Kristian ReichChief Scientific Officer Sell Plan 16,1052,808,446 held (−1%) $20.01 $322K -45.9% —
Jul 13SEC Da Silva Jorge SantosCEO Sell Plan 68,2892,774,893 held (−2%) $20.02 $1.4M -46.0% —
Jul 13SEC Da Silva Jorge SantosCEO Sell Plan 33,9362,843,182 held (−1%) $20.01 $679K -45.9% —
Jul 2SEC Da Silva Jorge SantosCEO Sell Plan 47,7752,877,118 held (−2%) $20.03 $957K -46.0% —
Jun 23SEC Matthias BodenstedtCFO Sell Plan 39,1201,115,435 held (−3%) $22.04 $862K -50.9% —
Jun 18SEC Matthias BodenstedtCFO Sell Plan 15,0821,157,349 held (−1%) $19.68 $297K -45.0% —
Jun 18SEC Matthias BodenstedtCFO Sell Plan 2,7941,154,555 held (−0%) $19.60 $55K -44.8% —
Jun 17SEC Kristian ReichChief Scientific Officer Sell Plan 50,0002,824,551 held (−2%) $19.43 $972K -44.3% —
Jun 17SEC Kristian ReichChief Scientific Officer Sell Plan 50,0002,924,551 held (−2%) $18.89 $944K -42.7% —
Jun 17SEC Kristian ReichChief Scientific Officer Sell Plan 50,0002,874,551 held (−2%) $18.70 $935K -42.1% —
May 13SEC Matthias BodenstedtCFO Sell Plan 13,6531,172,431 held (−1%) $20.02 $273K -46.0% —
Apr 16SEC Matthias BodenstedtCFO Sell Plan 2,4261,186,084 held (−0%) $19.56 $47K -44.7% —
Apr 14SEC Da Silva Jorge SantosCEO Sell 98,1272,976,766 held (−3%) $18.41 $1.8M -41.2% —
Apr 14SEC Da Silva Jorge SantosCEO Sell 51,8732,924,893 held (−2%) $18.23 $946K -40.6% —
Apr 10SEC Matthias BodenstedtCFO Sell Plan 85,8701,190,435 held (−7%) $18.94 $1.6M -42.9% —
Apr 10SEC Matthias BodenstedtCFO Sell Plan 1,9251,188,510 held (−0%) $19.51 $38K -44.5% —
Apr 2SEC Mark N LampertDirector Sell 1,932,3548,302,735 held (−19%) $16.79 $32.4M -35.6% —
Apr 2SEC Mark N LampertDirector Sell 1,569,1166,599,722 held (−19%) $16.79 $26.3M -35.6% —
Apr 2SEC Mark N LampertDirector Sell 248,5301,039,238 held (−19%) $16.79 $4.2M -35.6% —
Dec 10SEC Kristian ReichChief Scientific Officer Sell 130,00072,908 held (−64%) $15.08 $2.0M -28.2% —
Dec 10SEC Da Silva Jorge SantosCEO Sell 130,0002,948,577 held (−4%) $15.08 $2.0M -28.2% —
Dec 10SEC Kristian ReichChief Scientific Officer Sell 72,908 $14.43 $1.1M -25.0% —
Dec 10SEC Da Silva Jorge SantosCEO Sell 70,0002,878,577 held (−2%) $14.49 $1.0M -25.3% —
Oct 9SEC Matthias BodenstedtCFO Buy 10,870627,536 held (+2%) $9.09 $99K +19.0% —
Oct 1SEC Cormorant Global Healthcare Master Fund, LpFormer 10% Owner Sell 3,390,9434,800,000 held (−41%) $7.58 $25.7M +42.7% —
Oct 1SEC Cormorant Global Healthcare Master Fund, LpFormer 10% Owner Sell 2,800,0002,000,000 held (−58%) $6.61 $18.5M +63.7% —
Oct 1SEC Cormorant Global Healthcare Master Fund, LpFormer 10% Owner Sell 232,4608,190,943 held (−3%) $8.40 $2.0M +28.8% —
Oct 1SEC Cormorant Global Healthcare Master Fund, LpFormer 10% Owner Sell 70,7488,423,403 held (−1%) $9.38 $664K +15.4% —
Oct 1SEC Cormorant Global Healthcare Master Fund, LpFormer 10% Owner Sell 5,8271,994,173 held (−0%) $6.96 $41K +55.5% —

Insiders at MoonLake Immunotherapeutics

InsiderBoughtSoldLast filingScore
Mark N LampertDirector — $63.0M Apr 2, 2026 —
Cormorant Global Healthcare Master Fund, LpFormer 10% Owner — $46.9M Oct 1, 2025 —
Da Silva Jorge SantosCEO — $8.7M Jul 13, 2026 —
Kristian ReichChief Scientific Officer — $8.1M Jul 29, 2026 —
Matthias BodenstedtCFO $99K $3.2M Jun 23, 2026 —

MLTX stock: common questions

Are MoonLake Immunotherapeutics insiders buying MLTX stock?

In the past 12 months, 1 insiders reported open-market purchases of MLTX worth $99K. The latest was CFO Matthias Bodenstedt bought $99K of MLTX at $9.09 — first open-market purchase in our records.

Are MoonLake Immunotherapeutics insiders selling MLTX stock?

4 insiders reported sales worth $83.0M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is MLTX's 52-week range?

Over the past year MLTX has traded between $9.12 and $22.16. It last closed at $10.82 on Oct 9, 2026.